DiscoveryProbe™ FDA-approved Drug Library: A Comprehensive Resource for High-Throughput Drug Screening

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a curated collection of 2,320 bioactive compounds approved by global regulatory agencies, including the FDA, EMA, HMA, CFDA, and PMDA (APExBIO product page). Each compound is provided as a 10 mM DMSO solution, ensuring compatibility with automated high-throughput screening (HTS) and high-content screening (HCS) platforms. The library includes clinically validated drugs, such as doxorubicin and metformin, with well-characterized mechanisms of action (MOA), enabling drug repositioning and target identification (Saracatinib/MLKL study). The format supports reproducibility and long-term stability at specified storage conditions. Researchers have leveraged this library to identify necroptosis inhibitors, like saracatinib, in advanced disease models, demonstrating its translational power.

Biological Rationale

Clinically approved compound collections, such as the DiscoveryProbe™ FDA-approved Drug Library, enable researchers to interrogate human-relevant pharmacological space. Each compound in the library has passed regulatory review for efficacy and safety in at least one major jurisdiction, minimizing downstream translational risk (APExBIO). The library covers a spectrum of mechanisms, including receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators. This diversity permits systematic exploration of signaling pathways, disease models, and molecular mechanisms underlying pathologies such as cancer and neurodegenerative disorders (see mechanistic roadmap, which this article extends by providing updated benchmarks and clinical context). Researchers can repurpose known drugs for new indications, reducing development timelines and costs compared to de novo discovery.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library is designed to encompass drugs with well-annotated MOAs. Key mechanistic classes represented include:

• Receptor agonists/antagonists: e.g., beta-blockers, opioid antagonists.
• Enzyme inhibitors: e.g., statins, kinase inhibitors.
• Ion channel modulators: e.g., calcium channel blockers.
• Signal pathway regulators: e.g., mTOR inhibitors, JAK inhibitors.

For example, saracatinib, a clinically approved kinase inhibitor, was recently identified as an inhibitor of necroptosis by targeting the pseudokinase MLKL. Saracatinib interferes with MLKL phosphorylation, translocation, and oligomerization, thereby blocking TNF-induced necroptosis without inhibiting upstream kinases RIPK1 or RIPK3 (Saracatinib/MLKL study).

This mechanistic diversity enables screening for modulators of complex biological processes, including cell death pathways, immune responses, and metabolic regulation.

Evidence & Benchmarks

• Screening the DiscoveryProbe™ FDA-approved Drug Library enabled identification of saracatinib as a potent inhibitor of necroptosis in multiple cell types (Li et al. 2024, DOI).
• Saracatinib directly targets MLKL, as confirmed by molecular docking and thermal stability assays (Li et al. 2024, Fig. 2).
• Mutation of MLKL's saracatinib-binding site (Gln343Ala) reduces saracatinib efficacy, confirming target engagement (Li et al. 2024, Supplementary Data).
• The library format enables stable compound storage for 12 months at -20°C and up to 24 months at -80°C, supporting long-term experimental reproducibility (APExBIO).
• HTS and HCS workflows using this library have accelerated repositioning of drugs for oncology, neurodegeneration, and rare diseases (internal review; this article updates results with new clinical benchmarks).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library supports diverse biomedical applications:

• Drug repositioning screening: Identifies new uses for approved drugs (previous article; this work clarifies application boundaries).
• Pharmacological target identification: Enables systematic mapping of target-compound interactions.
• High-throughput and high-content cell-based assays: Facilitates mechanistic screens in cancer, infectious, and neurodegenerative disease models.
• Signal pathway regulation studies: Dissects regulatory networks using well-characterized compounds.

Common Pitfalls or Misconceptions

• The library does not provide unapproved experimental drugs; all compounds are clinically approved or listed in recognized pharmacopeias.
• It is unsuitable for identifying first-in-class chemical matter, as the focus is on approved drugs, not novel scaffolds.
• Compounds dissolved in DMSO may not be compatible with all cell types or assay formats; DMSO controls are essential.
• Use in in vivo animal models may require reformulation, as provided solutions are optimized for in vitro screening.
• The library does not replace validation studies; hits require downstream target confirmation and functional assays.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is formatted for direct integration into automated HTS and HCS pipelines. Compounds are provided in pre-dissolved 10 mM solutions in DMSO, compatible with 96-well microplates, deep well plates, and 2D barcoded tubes. Storage at -20°C (12 months) or -80°C (24 months) ensures compound integrity (product details). Shipping is available on blue ice for evaluation samples and at room temperature or on blue ice for larger volumes. Users are advised to include DMSO vehicle controls and confirm compound identities using provided documentation. Integration with data management systems is facilitated by 2D barcoding and standardized formats.

For recommendations on maximizing cell assay reproducibility with L1021, see this Q&A-driven protocol article; the current review provides updated stability and workflow details.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO is a validated, versatile resource that accelerates translational drug discovery. Its broad regulatory coverage, mechanistic diversity, and ready-to-use formats enable efficient drug repositioning and mechanistic mapping. Recent studies, such as the identification of saracatinib as an MLKL inhibitor, underscore the library’s value for uncovering new therapeutic strategies (Li et al. 2024). Ongoing advances in automated screening and data integration will further enhance the utility of this resource in disease model research, target identification, and precision medicine workflows. For ordering details and technical support, refer to the DiscoveryProbe™ FDA-approved Drug Library product page.